PEG-MGF

Typical use cases

Dosing guidelines

Titration

No validated titration schedule exists. Community/research practice typically begins at the lower end of the reported range and adjusts based on tolerance; framed neutrally, this reflects uncontrolled reports rather than clinical guidance.

Reconstitution

Reconstituted from lyophilized powder with bacteriostatic (or sterile) water added gently against the vial wall; the solution is allowed to dissolve with gentle swirling rather than shaking.

Injection sites

Injectable; reported as subcutaneous or intramuscular, with intramuscular injection into recently trained/target muscle groups described in muscle-focused research and community protocols.

Storage & handling

Lyophilized powder stored frozen (around -20°C) for long-term; once reconstituted, refrigerated at 2–8°C and commonly reported as used within about 14 days. Protect from light and heat.

Side effects

• Injection-site reactions (redness, swelling, soreness) Mild · Common
• Localized pump or tightness in the injected muscle Mild · Common
• Lightheadedness, flushing, or transient fatigue Mild · Uncommon
• Anti-PEG antibody formation with repeated exposure (theoretical, reduced efficacy) Moderate · Uncommon
• Theoretical concern of stimulating abnormal cell proliferation / tumor promotion Severe · Rare
• Satellite-cell pool depletion with chronic stimulation (theoretical) Moderate · Rare

Research summary

PEG-MGF is the pegylated form of Mechano Growth Factor (MGF), the C-terminal E-domain peptide of the IGF-1Ec splice variant that is naturally and transiently expressed in skeletal muscle after mechanical loading or damage. The evidence base is almost entirely preclinical: in vitro work indicates the MGF E-peptide activates quiescent muscle satellite (stem) cells and promotes myoblast proliferation while delaying premature differentiation (Yang & Goldspink, 2002). The downstream signaling is debated — early work suggested partial independence from the classical IGF-1 receptor, whereas later studies (Brisson & Barton, 2012) found the E-peptide's mitogenic and motogenic effects are in fact dependent on the IGF-1 receptor, so the mechanism remains unsettled. Rodent and cell studies have explored MGF in muscle injury models, and the E-domain peptide has shown cardioprotective effects in experimental myocardial infarction (e.g., localized polymeric delivery in Peña et al., 2015) as well as neuroprotective signals in animal/cell models. Native MGF has a very short half-life (on the order of minutes); pegylation increases the molecule's hydrodynamic radius and sterically shields it from proteases, which is reported to extend circulating activity and reduce dosing frequency. Notably, one growth-plate study found exogenous MGF peptide did not reproduce proliferative effects in chondrocytes, illustrating that responses are tissue- and context-dependent. There are no published human clinical trials, no established human pharmacokinetics, and no validated safety profile; reported research doses come from animal studies and uncontrolled community practice rather than rigorous human data. Additional theoretical concerns include cell-proliferation/tumor-promotion uncertainty, potential satellite-cell pool depletion with chronic stimulation, and anti-PEG antibody formation with repeated exposure; MGF/PEG-MGF is also a WADA-prohibited substance.

Key references

• https://pmc.ncbi.nlm.nih.gov/articles/PMC2840678/
• https://febs.onlinelibrary.wiley.com/doi/abs/10.1016/S0014-5793(02)02918-6
• https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0045588
• https://pmc.ncbi.nlm.nih.gov/articles/PMC4328136/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC3795771/

Related compounds